An observational study in Emphysema, sponsored by Pulmonx Corporation. Active, not recruiting at 11 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Pulmonx Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Emphysema with a site in United States — 21 open to participants now, 30 under way, 1 of them phase 3. Emphysema · United States.
Among the 162 studies in Emphysema with a site in United States, this one is the 27th largest by planned enrollment of the 45 observational ones that give a count, is one of 5 that started in 2019, is one of 46 observational ones, reaches primary completion later than 6 of the 29 other live ones, and was the 134th registered.
382 studies on the registry are indexed under Emphysema; 58 are open to participants now.
Browse Emphysema studies →21 of the 162 studies in Emphysema with a site in United States are open now. Recruiting first, the newest first:
Apreo Health, Inc. · Sites in United States
Ages 40–84
Eli Lilly and Company · Sites in United States, Argentina, Austria and 15 more countries
Ages 40–75
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Pulmair Medical, Inc. · Sites in United States
Ages 22+
The Cleveland Clinic · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Emphysema studies recruiting now, 27 (55%) set no upper age limit and 8 (16%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 39 · Phase 3 19 · Phase 4 13
First in 1978; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 131 across 111 observational studies indexed under Emphysema.
Median enrollment 74 across the 114 interventional studies, 196 across the 45 observational. Of the 119 that completed or were terminated, 52 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 162 have an industry lead sponsor. The 10 most frequent:
Pulmonx Corporation is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Pulmonx Corporation has 9 studies filed under Emphysema — fewer than ten, so there is no comparison to draw.
12 of the studies in Emphysema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04302272Olympus Corporation of the AmericasSTRIVE Post-Market Registry Study | 2026-12 |
| NCT05257681Beth Israel Deaconess Medical CenterInter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction | 2026-12-24 |
| NCT04801108Beth Israel Deaconess Medical CenterCombined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema | 2026-12-31 |
| NCT04186546Pulmonx CorporationZephyr Valve Registry (ZEVR) | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 162 studies in Emphysema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
The Zephyr Valve Registry (ZEVR) is a multi-center, single-arm, prospective Registry. The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of patients with hyperinflation associated with severe emphysema, in regions of the lung that have little to no collateral ventilation.
Approximately 150 patients undergoing Zephyr Valve treatment in the commercial setting will be enrolled and followed out to 3 years. Assessments will be conducted at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure. The Zephyr Valve Registry will be conducted at a minimum of 5, and a maximum of 10 clinical sites.
Subjects prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after determination of little to no collateral ventilation between target and ipsilateral lobes. Safety and effectiveness of the Zephyr Valve treatment will be evaluated post-treatment based on data collected out to 3 years after the treatment.
The Registry population will be comprised of subjects with hyperinflation of the lungs due to severe emphysema that are prescribed the Zephyr Valve treatment by their physician and confirmed to have little to no collateral ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zephyr Valve Procedure
Device: Zephyr Valve Procedure
The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
Also known as: Zephyr Endobronchial Valve, Endobronchial Valve, Bronchoscopic Lung Volume Reduction, BLVR
Incidence Rate of Pneumothorax from Baseline to 45-days post-procedure
The percentage of study participants undergoing the Zephyr Valve Procedure who develop a pneumothorax from the date of the procedure to 45-day post intervention.
Time frame: Baseline to 45-days post-procedure
Incidence Rate of Serious Adverse Events (SAEs) of Interest from Baseline to 3 years post-procedure
The percentage of study participants who experience a device and/or procedure related SAE including but not limited chronic obstructive pulmonary disease (COPD) exacerbation, hemoptysis, pneumonia, respiratory failure, Valve expectoration and Valve migration
Time frame: Baseline to 3 years post-procedure
Absolute Change in Treated Lobar Volume Reduction (TLVR) after 45-days post-procedure
The Treated Lobe Volume Reduction (TLVR) will be evaluated by quantitative analysis of high-resolution computed tomography (HRCT) scans at Baseline and at 45-days post-valve placement to measure the treated lobe volume reduction.
Time frame: At baseline and after 45-days post-procedure
Percent Change in Treated Lobar Volume Reduction (TLVR) after 45-days post-procedure
The Treated Lobe Volume Reduction (TLVR) will be evaluated by quantitative analysis of HRCT scans at Baseline and at 45-days post-valve placement to measure the treated lobe volume reduction.
Time frame: At baseline and after 45-days post-procedure
Absolute Change in Forced Expiratory Volume in 1 second FEV1 (L) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure
The mean absolute change in FEV1(L) relative to Baseline at 6-months, 12-months, 24-months and 36-months post procedure
Time frame: At baseline, 6-months, 12-months, 24-months and 36-months post-procedure
Percent Change in Forced Expiratory Volume in 1 second FEV1 (L) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure
The mean percent change in FEV1(L) relative to Baseline at 6-months, 12-months, 24-months and 36-months post procedure
Time frame: At baseline, 6-months, 12-months, 24-months and 36-months post-procedure
Absolute Change in Forced Expiratory Volume in 1 second FEV1 (% Predicted) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure
The mean absolute change in FEV1(% Predicted) relative to Baseline at 6-months, 12-months, 24-months and 36-months post procedure.
Time frame: At baseline, 6-months, 12-months, 24-months and 36-months post-procedure
Percent Change in Forced Expiratory Volume in 1 second FEV1 (% Predicted) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure
Mean percent change in FEV1(% Predicted) relative to Baseline at 6-months, 12-months, 24-months and 36-months post-procedure
Time frame: At baseline, 6-months, 12-months, 24-months and 36-months post-procedure
Absolute Change in Six-Minute Walk Distance (6MWD) from baseline to 6-months and 12-months post-procedure
Mean absolute change in the 6MWD from Baseline to 6-months and 12-months post-procedure.
Time frame: At baseline, 6-months and 12-months
Percent Change in Six-Minute Walk Distance (6MWD) from baseline to 6-months and 12-months post-procedure
Mean percent change in the 6MWD from Baseline to 6-months and 12-months post-procedure.
Time frame: At baseline, 6-months and 12-months
Absolute Change in St. George's Respiratory Questionnaire (SGRQ) Total Score from baseline to 6-months and 12-months post-procedure
Mean absolute change in the St. George's Respiratory Questionnaire Total Score from Baseline to 6-months and 12-months post-procedure. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At baseline, 6-months and 12-months
Percent Change in St. George's Respiratory Questionnaire (SGRQ) Total Score from baseline to 6-months and 12-months post-procedure
Mean percent change in the St. George's Respiratory Questionnaire Total Score from Baseline to 6-months and 12-months post-procedure. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At baseline, 6-months and 12-months
Absolute Change in BODE Index Total Score from baseline to 6-months and 12-months post-procedure
BODE stands for Body mass index, airflow Obstruction, Dyspnea and Exercise capacity. The BODE Index is a tool used to predict the death risk by using an algorithm that considers the following variables: body mass index (BMI, B), airflow obstruction (O) as measured by the post-bronchodilator FEV1 (percentage of predicted value), dyspnea (D) assessed by the modified Medical Research Council (MMRC) score, and exercise tolerance (E) measured by 6 minute walking distance. These variables are graded 0 to 3 (0 or 1 for BMI) and summed to give a total score between 0 and 10. The resulting score is called the BODE index, with higher scores indicating a greater risk of death. The mean absolute change in the BODE score will be calculated from baseline scores compared to the BODE score at 6 months and 12 months post procedure.
Time frame: At baseline, 6-months and 12-months
Percent change in BODE Index Total Score from baseline to 6-months and 12-months post-procedure
BODE stands for Body mass index, airflow Obstruction, Dyspnea and Exercise capacity. The BODE Index is a tool used to predict the death risk by using an algorithm that considers the following variables: body mass index (BMI, B), airflow obstruction (O) as measured by the post-bronchodilator FEV1 (percentage of predicted value), dyspnea (D) assessed by the modified Medical Research Council (MMRC) score, and exercise tolerance (E) measured by 6 minute walking distance. These variables are graded 0 to 3 (0 or 1 for BMI) and summed to give a total score between 0 and 10. The resulting score is called the BODE index, with higher scores indicating a greater risk of death. The mean percent change in the BODE score will be calculated from baseline scores compared to the BODE score at 6 months and 12 months post procedure.
Time frame: At baseline, 6-months and 12-months
Plan to share: Undecided
Started Nov 2019 (actual). Primary completion is estimated for Dec 2026, 85 months after the start.
Of 45 observational studies under Emphysema, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 35. This study's planned 85 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonx Corporation